Ascendis Pharma Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Jan Mikkelsen
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 18yrs |
| CEO ownership | 0.7% |
| Management average tenure | 9.3yrs |
| Board average tenure | 7.9yrs |
Recent management updates
Recent updates
Here's My Prediction For Who Could Acquire Ascendis Pharma
Dec 15Ascendis Pharma: Rare Disease Player Is A Buy On Yorvipath Launch Trajectory
Apr 14Optimistic Investors Push Ascendis Pharma A/S (NASDAQ:ASND) Shares Up 26% But Growth Is Lacking
Mar 13
Ascendis Pharma A/S (NASDAQ:ASND) Yearly Results: Here's What Analysts Are Forecasting For This Year
Feb 15Ascendis Pharma: Danish Blockbuster Hunter
Jan 29
Anticipated YORVIPATH Launch And SKYTROFA Blockbuster Potential Drive Optimism For Future Growth
Expansion in hypoparathyroidism treatment and growth hormone products drives substantial revenue growth, leveraging a robust commercialization strategy.Ascendis Pharma Takes A Big Price Cut On Skytrofa
Sep 05Ascendis Pharma's Ambitious Vision 2030
Jan 11CEO
Jan Mikkelsen (65 yo)
Mr. Jan Moller Mikkelsen is President, CEO, Member of Executive Board & Executive Director of Ascendis Pharma A/S from December 2007. He joined the Ascendis Pharma A/S in December 2007. He is Chairman of t...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 18yrs | no data | 0.72% $ 91.6m | |
| CFO, Executive VP & Member of Executive Board | 9.3yrs | no data | 0.0066% $ 838.9k | |
| Executive VP | 18yrs | no data | 0.0094% $ 1.2m | |
| Executive VP | 12.5yrs | no data | 0% $ 0 | |
| Senior VP | 1.8yrs | no data | 0.00032% $ 40.9k | |
| Vice President of Investor Relations | no data | no data | no data | |
| Executive Vice President of Product Supply & Quality | 10.3yrs | no data | 0.0094% $ 1.2m | |
| Executive VP and Head of Research & Product Development | 9.9yrs | no data | 0.011% $ 1.4m | |
| Executive VP & Head of Clinical Development for Oncology | 3.9yrs | no data | no data | |
| Head of U.S. Commercial of Endocrinology | 3.6yrs | no data | no data | |
| Chief Business Officer | 1.3yrs | no data | no data | |
| Executive VP & President of Ascendis US | less than a year | no data | no data |
Experienced Management: ASND's management team is seasoned and experienced (9.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 18yrs | no data | 0.72% $ 91.6m | |
| Independent Chairman | 11.1yrs | €139.72k | 0.0018% $ 227.3k | |
| Independent Director | 3.3yrs | €73.01k | 0.00027% $ 34.5k | |
| Independent Director | 8.7yrs | €92.64k | 0.0018% $ 227.3k | |
| Independent Director | 7.1yrs | €96.17k | 0.0026% $ 333.3k | |
| Independent Director | 3.3yrs | €69.48k | 0.00060% $ 76.6k |
Experienced Board: ASND's board of directors are considered experienced (7.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/28 02:15 |
| End of Day Share Price | 2025/12/26 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ascendis Pharma A/S is covered by 28 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Michelle Gilson | Canaccord Genuity |
| Alethia Young | Cantor Fitzgerald & Co. |